![](https://hitconsultant.net/wp-content/uploads/2024/05/IMG_3480-1500x1000.jpeg)
What you should know:
– Activate Injections, Inc. (“Activate”)a healthcare innovation company that develops and manufactures the enFuse® portable drug delivery platform and Serina Therapeutic (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its POZ Platform™ to develop and improve efficacy and safety across multiple modalities, including small molecules, RNA and antibody drug conjugates (ADC). , today announced a partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse for the treatment of Parkinson's disease.
– SER-252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopamine stimulation (CDS).
Serina partners with Enable to deliver innovative Parkinson's disease drugs
CDS has been shown to reduce the severity of levodopa-related motor complications, such as dyskinesia, in Parkinson's disease. Preclinical studies indicate that SER-252 can deliver CDS without causing skin reactions. Serina plans to begin clinical testing of SER-252 in 2025.
enFuse is an innovative, portable drug delivery platform designed for subcutaneous delivery of large volumes of medications. This system allows patients to receive treatment via a simple injection under the skin, avoiding the need for intravenous administration. enFuse addresses the limitations of IV infusions and other subcutaneous methods by providing rapid, simple and convenient administration, allowing patient self-administration and benefiting patients, healthcare providers and payers.
Enable is collaborating with multiple pharmaceutical partners to conduct clinical trials and plan joint commercial launches of therapies using enFuse technology. Enable is selectively expanding its pharmaceutical partnerships to include treatments and patient populations that will benefit from enFuse. The first enFuse combination product received approval from the U.S. Food and Drug Administration in 2023.
Under the terms of the agreement, Serina will receive an exclusive global license to the enFuse platform in exchange for upfront payments and milestones. Enable will also receive a share of product sales and single-digit royalties.
“Current apomorphine treatments require daily, lengthy infusions via an electronic pump, which not only overburdens patients and providers, but can also cause significant skin reactions,” said Randall Moreadith, MD, Ph.D. ., director of development at Serina Therapeutics. “With enFuse, patients can self-administer SER-252 from the comfort of their home using portable technology and rapid treatment time. If effective, a combination of SER-252 and enFuse offers the ability for patients to remain in a continuous “ON” state and avoid dyskinesia. »